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Abstract
Background: Information about the achievement of glycemic targets in patients with type 2 diabetes according to
different individualization strategies is scarce. Our aim was to analyze the allocation of type 2 diabetic patients into
individualized glycemic targets according to different strategies of individualization and to assess the degree of
achievement of adequate control.
Methods: Cross-sectional analysis on 5382 type 2 diabetic patients in primary care setting in Spain between 2011
and 2012. Targets of HbA1c were assigned based on different strategies of individualization of glycemic targets: 1)
the ADA/EASD consensus 2) The Spanish Diabetes Society (SED) consensus 3) a strategy that accounts for the risk
of hypoglycemia (HYPO) considering the presence of a hypoglycemia during the last year and type of
hypoglycemic treatment. Concordance between the different strategies was analyzed.
Results: A total of 15.9, 17.1 and 67 % applied to ADA/EASD recommendation of HbA1c target of <6.5, < 7 and <8 %
(48, 53 and 64 mmol/mol), and 31.9 and 67.4 % applied to the SED glycemic target of <6.5 and <7.5 % (<48 and
58 mmol/mol). Using the HYPO strategy, 53.5 % had a recommended HbA1c target <7 % (53 mmol/mol). There is a
94 % concordance between the ADA/EASD and SED strategies, and a concordance of 41–42 % between
these strategies and HYPO strategy. Using the three different strategies, the overall proportion of patients
achieving glycemic targets was 56–68 %.
Conclusions: Individualization of glycemic targets increases the number of patients who are considered adequately
controlled. The proposed HYPO strategy identifies a similar proportion of patients that achieve adequate
glycemic control than ADA/EASD or SED strategies, but its concordance with these strategies in terms of
patient classification is bad.
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Background
Recent clinical guidelines and expert committees on the
management of type 2 diabetes have recommended
individualization of glycemic targets based on patient
characteristics, comorbid conditions, diabetes complica-
tions, duration of diabetes and risk of hypoglycemia [1–4].
The American Diabetes Association and European Associ-
ation for the Study of Diabetes (ADA/EASD) [2] recom-
mended a target HbA1c level <7 % (53 mmol/mol) for
most patients with type 2 diabetes, however, a more re-
laxed target (HbA1c 7.5–8 % (58–64 mmol/mol)) should
be aimed in patients with multiple comorbidities, reduced
life expectancy, history of hypoglycemia, or advanced dia-
betes complications. On the other hand, a more stringent
target such as HbA1c <6.5 % (48 mmol/mol) was consid-
ered beneficial in younger patients without comorbid
conditions and with no adverse effects of antihyperglyce-
mic treatment. Similarly, the national consensus from the
Sociedad Española de Diabetes (SED – Spanish Diabetes
Society) [3] recommended a stringent HbA1c target of
<6.5 % (48 mmol/mol) in patients with newly diagnosed
diabetes, age <70 years, and absence of diabetic
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complications, otherwise, a less stringent HbA1c goal of
<7.5 % (58 mmol/mol) should be the target in the absence
of these conditions. The American Association of Clin-
ical Endocrinologists (AACE) also recommends the
individualization of glycemic targets taking into ac-
count several factors that include concurrent illnesses
and risk of hypoglycemia [5].
Despite the widespread acceptance of individualized gly-
cemic control in patients with type 2 diabetes, information
on the number of patients reaching these new recom-
mended targets in different populations is scarce [6–8]. A
recent analysis from the National Health and Nutrition
Examination Survey (NHANES) revealed that about half
of the US diabetic population would be considered inad-
equately controlled if a universal HbA1c target of <7 %
(53 mmol/mol) was applied, compared with 30 % if using
individualized ADA glycemic targets [6, 7]. In the analysis
by Laiteerapong et al. [6], individualization of glycemic
targets was performed taking into account the patient’s
age, duration of diabetes, diabetes complications and sig-
nificant comorbidities, but not the risk and the past his-
tory of hypoglycemia. Likewise, the study by Graciani et
al. [8], conducted in 661 Spanish type 1 and type 2 dia-
betic patients, does not consider the risk of hypoglycemia,
and information regarding diabetes complications was
limited to cardiovascular disease and nephropathy. History
of past hypoglycemia and insulin treatment are known
and important predictors of a future hypoglycemic event
[9–11], and, as stated in different recommendations, are
important aspects to consider when assigning a patient to
a certain HbA1c target.
In the Spanish type 2 diabetic population included in
the Diabcontrol Study [12], we analyzed the distribution
of patients within the individualized glycemic targets
recommended by the ADA/EASD and the SED consen-
sus and according to an original strategy that considered
risk of hypoglycemia. Furthermore, we compare the dif-
ferent strategies of individualization of glycemic targets
and their concordance and provide information concern-




Patients included in this analysis participated in the Dia-
bcontrol Study previously described [12]. Briefly, this
was an epidemiological, cross-sectional study conducted
in primary care centers throughout Spain between 2011
and 2012, which included 5382 patients with type 2 dia-
betes receiving antidiabetic treatment. All patients com-
pleted a single clinical visit in which HbA1c was
measured in capillary blood (A1CNow+) [13].
We identified clinical variables used in the ADA/EASD
[2] and SED consensus [3]. Young age was considered
≤70 and ≤75 years for the SED and ADA/EASD strat-
egies, respectively, whereas long duration of diabetes
was defined as > 10 years for both strategies. The
presence of micro- and macro-vascular disease was ex-
tracted from the clinical database and included the pres-
ence of macroalbuminuria (urine albumin-creatinine
ratio of >300 mg/g), glomerular filtration rate < 60 ml/
min/1.73 m2, diabetic foot, diabetic retinopathy, poly-
neuropathy, peripheral vascular disease, cerebrovascular
disease and coronary vascular disease. We also reviewed
information on antihyperglycemic treatment and history
of a hypoglycemia that required medical assistance dur-
ing the 12 months prior to the study visit. Patients with
missing data concerning any variable necessary for pa-
tient classification were not included in the analysis.
Table 1 shows the strategies for assigning patients with
type 2 diabetes into different categories of HbA1c: 1)
ADA/EASD strategy considered patient’s age, duration
of diabetes and presence of advanced micro- and macro-
vascular complications; 2) SED strategy considered pa-
tient’s age, duration of diabetes and the presence of ad-
vanced micro- and macro-vascular complications; and 3)
The HYPO strategy considered the type of hypoglycemic
treatment and the need for medical assistance due to an
hypoglycemic event during the 12 months prior to the
study visit. In order to determine the concordance
between the three strategies, each one was simplified
into two categories named low and high risk. In
addition, we evaluated the impact of taking into account
hypoglycemia risk in the ADA/EASD and SED strategies.
Patients with a previous hypoglycemic episode or treated
with two or more insulin doses were directly classified
into highest risk categories from the ADA/EASD and
SED consensus.
The study was approved by the Unitat d’Avaluació,
Suport i Prevenció (UASP) of Hospital Clínic in
Barcelona and was conducted according to the princi-
ples of the Declaration of Helsinki and Good Clinical
Practice standards. We obtained written informed
consent from all patients before their inclusion in the
study.
Statistical analysis
The results were expressed as frequencies and per-
centages for qualitative variables and as mean and
standard deviation for quantitative variables. Missing
data can be inferred by the total number of patients
included in each analysis. Cohen’s kappa coefficient
was used to evaluate the concordance between the
different strategies of patient classification. All statis-
tical tests were considered significant at p < 0.05. Stat-
istical analysis was performed with the SAS statistical
package (version 9.3).
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Results
Patient characteristics
A total of 5382 individuals with type 2 diabetes were in-
cluded in the study. Patient characteristics and
hypoglycemic treatment are shown in Table 2. The mean
age was 66.7 years, and 53 % were men. Diabetes com-
plications were present in 43.6 % of the population.
Average HbA1c was 7.3 ± 1.2 % (56 ± 9.2 mmol/mol)
and 48.6 % of the patients had an HbA1c of < 7 %
(53 mmol/mol).
Individualization of glycemic targets based on ADA/EASD
consensus (n = 5267)
Using the ADA/EASD consensus and including informa-
tion regarding patients’ age, duration of diabetes and the
presence of diabetic complications, a target HbA1c of <
6.5 % (48 mmol/mol) applied to 15.9 % of the study
population, while the conventional target of < 7 %
(53 mmol/mol) applied to 17.1 %. On the other hand, a
less stringent target (HbA1c < 8 % (64 mmol/mol)) ap-
plied to 67 % of our type 2 diabetic patients. According
Table 1 Strategies for individualization of glycemic targets







ADA/EASD- 1 <6.5 Low Any Any Any <5 No
ADA/EASD-2 <7 Low Any Any ≤75 5-9 No
ADA/EASD-3 <8 High Any Any >75 Any Any
Any >10 Any
Any Any Yes
SED-1 ≤6.5 Low Any Any ≤70 <10 No
SED-2 ≤7.5 High Any Any >70 Any Any
Any >10 Any
Any Any Yes
HYPO-1 <7 Low Not insulin, not SU, not glinides No Any Any Any
HYPO-2 <7.5 Low Basal insulin, SU, or glinides No Any Any Any
HYPO-3 <8 High Insulin (≥2 doses) Any Any Any Any
Any Yes Any Any Any
aDiabetes complications for ADA/EASD and SED categories were considered to be macroalbuminuria (urine albumin-creatinine ratio of >300 mg/g), chronic kidney
disease (CKD), diabetic foot, diabetic retinopathy, polyneuropathy, peripheral vascular disease, cerebrovascular disease or coronary vascular disease
SU: sulphonylureas
Table 2 Patient characteristics and hypoglycemic treatment
Sex (% men) 53
Age (years) 66.7 ± 10.8
BMI (kg/m2) 29.9 ± 5
Duration of diabetes (years) 8.8 ± 6.3
HbA1c (%/mmol/mol) 7.3 ± 1.2/56 ± 9.2
Diabetes complications (%) 43.6
Macrovascular 23
Microvascular 23.5
Hypoglycemic treatment (%) Oral agents (OA) only 77.7
•Sulphonylureas or glinides 26.7
Insulin with/without OA 22.3
•≥2 doses 9.3
Previous hypoglycemia that required medical assistance during the last year (%) 6.8
Data expressed as Mean ± SD/% of total
BMI: body mass index
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to these individualized glycemic targets, 67.4 % of our
population was considered adequately controlled.
When antihyperglycemic treatment and the presence
of a hypoglycemia during the last year were included in
the ADA/EASD strategy for individualization of HbA1c
targets, the percentage of patients corresponding to a
more stringent, conventional and less stringent target
were 14.9, 15.5 and 69.6 %, respectively. According to
these criteria, 68.5 % of the patients were considered ad-
equately controlled. The level of concordance between
the two risk stratification strategies is 97.5 % (kappa
coefficient 0.9413; data not shown).
Individualization of glycemic targets according to the SED
guidelines (n = 5267)
Using the SED consensus, an HbA1c target of < 6.5 %
(48 mmol/mol) applied to 31.9 % of the study popula-
tion, whereas a less stringent target of < 7.5 % (58 mmol/
mol) applied to 68.1 %. If these individualized glycemic
targets were considered, 55.2 % of our patients would be
adequately controlled. If patients with a previous history
of hypoglycemia that required medical assistance during
the last year and/or patients taking ≥ 2 insulin injections
were directly considered within the SED-2 category, the
percentages of patients corresponding to the more strin-
gent and the less stringent target would be 29.4 and
70.6 %, respectively. If these targets were used, 56 % of
our patients would be adequately controlled. The level
of concordance between the two risk stratification strat-
egies is 97.5 % (kappa coefficient 0.9403; data not
shown).
Individualization of glycemic targets based only on
antihyperglycemic treatment and the presence of
hypoglycemia during the last year (n = 5304)
When we stratified patients according to antihyperglyce-
mic treatment and the presence of hypoglycemia during
the last year, as shown in Table 1, 53.5 % were consid-
ered to have a low risk of hypoglycemia, and therefore
corresponded to a target of HbA1c < 7 % (53 mmol/
mol). A target of HbA1c < 7.5 % (58 mmol/mol) applied
to 32.6 % of the population and a less stringent target of
HbA1c < 8 % (64 mmol/mol) applied to 13.9 %. When
using this simple strategy of individualizing glycemic tar-
gets, 60.7 % of the population was considered to have an
adequate glycemic control according to the capillary
HbA1c (A1CNow+) measured at the single study visit.
Concordance between the different strategies of
individualizing glycemic targets
The level of concordance between the ADA/EASD strat-
egy and the SED consensus is very good, whether or not
they include information regarding past history of
hypoglycemia and diabetes treatment, with a concordance
of 94 and 94.3 %, respectively (Table 3). However, the level
of concordance between the strategy based only on anti-
hyperglycemic treatment and history of hypoglycemia
(HYPO) and the ADA/EASD and SED strategies was 42
and 41 %, respectively (Table 4).
Discussion
The individualization of glycemic targets using different
recommended strategies, such as the ADA/EASD
strategy used by Laiteerapong et al. [2, 6] or the SED
consensus strategies [3], reveals that 56–68 % of Spanish
diabetic patients receiving pharmacological treatment
are under adequate metabolic control. A similar propor-
tion of patients with adequate glycemic control was ob-
tained when individualization of targets were based only
on the risk of suffering a hypoglycemic episode. We
found a close agreement on the concordance of ADA/
EASD and SED strategies with regards of patient classifi-
cation; however, the concordance between these strat-
egies and the HYPO strategy that is based on the risk of
hypoglycemia was low. Of interest, the inclusion of a
history of hypoglycemia and type of hypoglycemic treat-
ment into the ADA/EASD and SED strategies does not
modify patient classification into different glycemic
targets.
Using the conventional HbA1c target level of < 7 %
(53 mmol/mol), 48.6 % of the Spanish type 2 patients
under pharmacological treatment at primary care cen-
ters are adequately controlled. Previous studies con-
ducted in Spanish patients reported a mean HbA1c
between 7 and 7.5 % (53 and 58 mmol/mol) with 40–
56 % of patients achieving HbA1c < 7 % (53 mmol/mol)
[14–19]. Differences between our findings and previous
studies can be explained in part by the fact that in this
study all patients were receiving pharmacological treat-
ment, while in some previous studies 23 % of patients
were treated with diet only and 77 % of patients were
treated with antidiabetic agents [16–18]. Furthermore, in
the absence of an integrated care system for diabetes
management, variations in diabetes management among
the different primary care settings may have contributed
[20].
Recent studies have questioned whether the conven-
tional target of HbA1c 7 % (53 mmol/mol) for defining
adequate glycemic control is suitable for all type 2 dia-
betic patients. The relationship between glucose control
and the development of micro- and macro-vascular
complications of diabetes is well established [21]. Results
from the UKPDS revealed that glycemic control pre-
vented microvascular complications; however, intensive
glucose control had minor effect in the development of
macrovascular complications [22]. Several trials in pa-
tients with type 2 diabetes have investigated the effects of
intensive glucose lowering on cardiovascular events. The
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ACCORD (Action to Control Cardiovascular Risk in Dia-
betes) trial had to be stopped because of an increase in all-
cause and cardiovascular mortality in the intensive gly-
cemic control group [23]. Two other trials, ADVANCE
(Action in Diabetes and Vascular Disease) [24] and VADT
(Veterans Affairs Diabetes Trial) [25], reported weight
gain and an increase in the rate of hypoglycemia with no
benefit in terms of preventing macrovascular complica-
tions in the intensive glucose management arms. These
findings have led to the development of several consensus
documents on the individualization of glycemic targets
according to patient’s characteristics [1–3]. As the
individualization of glycemic targets is a new concept in
diabetes care, information regarding the degree of gly-
cemic control according to these new targets is very lim-
ited. Laiteerapong et al. have recently published data
about the degree of glycemic control in type 2 adult dia-
betic patients in the US and find that 70 and 71 % of the
population would be adequately controlled according to
the ADA guidelines and the Ismail-Beigi strategy, respect-
ively. In order to make results comparable, we have strati-
fied our population of Spanish type 2 diabetic patients
according to the similar criteria of the ADA/EASD con-
sensus used by Laiteerapong et al. and have found
that 67.4 % of our patients can be considered ad-
equately controlled, a very similar proportion to the
US population, especially if we consider the greater
difficulty of achieving targets in patients with pharma-
cological treatment [17, 26].
The presence of a previous episode of hypoglycemia as
well as the choice of antidiabetic therapy, in particular in
patients receiving complex insulin regimens, has consist-
ently been reported as a strong predictor of
hypoglycemia [9–11]. Actually, some of the strategies for
individualization of glycemic targets including the ADA/
EASD consensus [2] and the Ismail-Beigi strategy [1]
take this information into account when assigning pa-
tients to a certain HbA1c target. In our analysis, the in-
clusion of information on hypoglycemia and treatment
with ≥ 2 insulin injections/day as risk markers of
hypoglycemia risk in the ADA/EASD strategy results in
similar percentages of patients corresponding to each
HbA1c target. Although the SED strategy does not take
into account the patient’s risk of hypoglycemia, when we
included the same markers of hypoglycemia risk into the
highest risk category, the concordance with the classical
SED classification is also very good. This led us to be-
lieve that taking into account information regarding pa-
tients’ risk of hypoglycemia may represent a simple and
feasible way of assigning patients to different HbA1c
targets. However, our results show a low degree of con-
cordance with previously described strategies in terms of
assigning patients to pre-specified glycemic targets (41–
42 % of concordance with kappa coefficients < 0.1). As
shown in Table 4, 55.5 and 56.5 % of patients were clas-
sified into highest risk categories according to the ADA/
Table 3 Concordance between the ADA/EASD and SED strategies in terms of patient classification
SED
ADA/EASD Low Risk (n(%)) High Risk (n(%)) Total (n(%)) Pa,b
Low Risk 1517 (30.3) 91 (1.8) 1608 (32.1) <0.0001
High Risk 211 (4.2) 3195 (63.7) 3406 (67.9)
Total 1728 (34.5) 3286 (65.5) 5014 (100)
SED + HYPO
ADA/EASD + HYPO Low Risk (n(%)) High Risk (n(%)) Total (n(%)) Pa,c
Low Risk 1395 (27.8) 85 (1.7) 1480 (29.5) <0.0001
High Risk 200 (4) 3334 (66.5) 3534 (70.5)




Table 4 Concordance between the risk of hypoglycemia
strategy (HYPO) and the ADA/EASD and SED strategies in terms
of patient classification
HYPO
ADA/EASD Low Risk (n(%)) High Risk (n(%)) Total (n(%)) Pa,b
Low Risk 1583 (30.5) 134 (2.5) 1717 (33) <0.0001
High Risk 2282 (55.5) 595 (11.5) 2877 (67)
Total 3865 (86) 729 (14) 4595 (100)
HYPO
SED Low Risk (n(%)) High Risk (n(%)) Total (n(%)) Pa,c
Low Risk 1463 (29.5) 128 (2.5) 1591 (32) <0.0001
High Risk 2804 (56.5) 572 (11.5) 3376 (68)
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EASD and SED consensus but into low risk category ac-
cording to the HYPO strategy; this explains the low
degree of concordance between the different strategies.
Several limitations of this study should be noted.
We only considered two recommended strategies for
individualization of glycemic targets among the
amount of them published and there is a lack of in-
formation concerning different psychosocial and eco-
nomic contexts, factors included in the ADA/EASD
strategy [2]. It should also be noticed that, HbA1c
was measured by a capillary method (A1CNow+),
which although not being standardized, it has a good
correlation with NGSP standardized techniques [13].
Strengths of this study include the fact that clinical in-
formation is collected from a primary care clinical data-
base, excluding possible bias from self-reporting.
Furthermore, we add information regarding past history
of hypoglycemia and severe retinopathy or diabetic foot,
which could not be included in the study by Laiteera-
pong et al. [6] and we use the same method of HbA1c
determination in every patient. Finally, it should be
noted that our study sample was recruited between 2011
and 2012, while the population sample included in the
US analysis was recruited between 2007 and 2008. So,
although the adoption of guideline recommendations for
individualization is slow and ongoing, our analysis may
reflect not only the degree of control of our population,
but also how professionals are applying the new
recommendations.
Conclusion
In conclusion, our results indicate that the new recom-
mendations for implementation of individualized gly-
cemic targets lead to a higher number of patients that
can be considered to have adequate glycemic control.
The ADA/EASD and SED strategies of individualizing
glycemic targets are in high degree of concordance, with
67–68 % of patients that correspond to a less stringent
target than the conventional HbA1c < 7 % (53 mmol/
mol). However, this should not lead to complacency,
since 30–45 % of patients still fail to meet the required
targets. Long-term studies are needed to determine if
the new strategy recommendations will lead to a reduc-
tion of diabetic complications and hypoglycemia in pa-
tients with diabetes. Waiting for these results, all current
strategies are important but incomplete and need to be
complemented by a clinical judgment to determine ef-
fective and safe glycemic targets.
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